A vaccine to combat Ebola has received regulatory approval for human testing in the UK, marking the first of four vaccines in development to enter clinical trials. Scientists at the University of Oxford initiated vaccine development eight weeks prior following a public health emergency declaration.
The current Ebola outbreak, primarily affecting the Democratic Republic of the Congo, has resulted in 625 deaths with 1,792 laboratory-confirmed cases. The disease is caused by the Bundibugyo species of Ebola, which has triggered two previous outbreaks. Unlike other Ebola strains, this variant lacks approved treatments or vaccines, intensifying the urgency of vaccine development. The ongoing conflict situation in the affected region, combined with highly mobile populations, has elevated the importance of vaccination efforts to contain disease spread.
The clinical trial will enroll 50 healthy adults aged 18-55, with initial doses expected to be administered within weeks. Participants will undergo monitoring for a year, though researchers anticipate rapid assessment of immune response and any adverse effects. The Oxford team leveraged the viral vector technology utilized in the COVID-19 vaccine, significantly accelerating development. The approach involves a genetically modified chimpanzee cold virus that delivers genetic material from the Bundibugyo species, prompting the immune system to produce a single Ebola viral protein without causing infection.
The vaccine has undergone testing in mice and macaque monkeys and is being manufactured to clinical standards by the Serum Institute of India, with approximately 620,000 doses already stockpiled. The UK Medicines and Healthcare Products Regulatory Agency authorized human trials based on this data. Researchers emphasized that while development timelines have been compressed through parallel testing protocols, all standard safety evaluations remain intact.
Three additional vaccine candidates are under development by Moderna, the International Aids Vaccine Initiative, and Public Health Vaccines, employing mRNA technology and established methods for other Ebola variants. Researchers are also coordinating with partners in Uganda to prepare for African trials. Potential risks including rare blood clotting complications are being carefully communicated to volunteers, though specialists note that the mortality rate from Bundibugyo Ebola, approximately one-third of those infected, substantially exceeds known vaccine risks.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI